Evidence map›Paper›PMID 40676628›Full record

ArticleMolecular cancer2025

Double vulnerability of active-NRF2 lung squamous cell carcinoma to NRF2 and TRIM24.

Miriam Sánchez-Ortega, Antonio Garrido, Lorena Sanz, Rafael Torres-Pérez, Carmen Hernandez, Alvaro Gutierrez-Uzquiza, Ming Sound Tsao, Ana Clara Carrera

Abstract read
In one paragraph

Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miriam Sánchez-OrtegaDepartment of Immunology and Oncology, Scientific Research Council (CSIC), Centro Nacional de Biotecnología, Autónoma University Madrid, Cantoblanco, Madrid, E-28049, Spain.
Antonio GarridoNanocaging Research Group, Department of Biosciences, School of Biomedical and Health Sciences, European Univ of Madrid, Villaviciosa de Odón, Madrid, E-28670, Spain.
Lorena SanzDepartment of Immunology and Oncology, Scientific Research Council (CSIC), Centro Nacional de Biotecnología, Autónoma University Madrid, Cantoblanco, Madrid, E-28049, Spain.
Rafael Torres-PérezDepartment of Immunology and Oncology, Scientific Research Council (CSIC), Centro Nacional de Biotecnología, Autónoma University Madrid, Cantoblanco, Madrid, E-28049, Spain.
Carmen HernandezDepartment of Immunology and Oncology, Scientific Research Council (CSIC), Centro Nacional de Biotecnología, Autónoma University Madrid, Cantoblanco, Madrid, E-28049, Spain.
Alvaro Gutierrez-UzquizaDepartment of Biochemistry and Molecular Biology, Pharmacy Faculty, Complutense University of Madrid, Madrid, Spain.
Ming Sound TsaoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ana Clara CarreraDepartment of Immunology and Oncology, Scientific Research Council (CSIC), Centro Nacional de Biotecnología, Autónoma University Madrid, Cantoblanco, Madrid, E-28049, Spain. acarrera@cnb.csic.es.

Funding

adrid Regional Government S2020/BMD-7321CIHR FDN-148395.European COST Action CA20121Fundación Científica Asociación Española Contra el Cáncer 16035CARRMinisterio de Ciencia e Innovación PID2019-106937RB-I00 PIA12019; PDC-2022-133912-I00)
6 · The paper itself

Abstract

Lung squamous cell cancer (LUSC) is associated with very poor survival due to the lack of specific treatments. A common genetic alteration in LUSC involves mutations in NFE2L2 (protein named NRF2) or its regulator, KEAP1, resulting in increased activity of the NRF2 transcription factor (TF). This study compares the requirement for active-NRF2 in LUSC cell lines. Although normal-NRF2 cells are more sensitive to oxidative stress, they do not require NRF2 for survival under non-stress conditions, in contrast, LUSC cells with active-NRF2 mutations depend on NRF2 for viability. NRF2 depletion in patient-derived organoid cultures with active-NRF2 as well as in xenografts with active-NRF2 triggers cell death. The focus of this study is to find genes that rescue cell death upon NRF2-depletion in active-NRF2 cells. A CRISPRa/dCas9 screening for gene targets capable of rescuing cell survival in these cells identified TRIM24 as a gene whose expression saves cell survival in NRF2-depleted active-NRF2 LUSC cells. Alongside oxidative stress, the lack of TRIM24 selectively contributed to the induction of cell death (apoptosis and ferroptosis) in active-NRF2 LUSC cells. Cells with a high NFE2L2/KEAP1 copy number ratio also undergo cell death. The increase in cell death observed upon TRIM24 depletion involves a reduction of TRIM24/PI3Kα complexes which destabilizes the PI3Kα catalytic subunit. Notably, overexpression of PI3Kα rescues cell survival in TRIM24-depleted active-NRF2 cells. These findings point to novel therapeutic approaches in LUSC.

Indexed as

Carcinoma, Squamous CellCarrier ProteinsLung NeoplasmsNF-E2-Related Factor 2AnimalsCell Line, TumorCell SurvivalGene Expression Regulation, NeoplasticHumansKelch-Like ECH-Associated Protein 1MiceOxidative StressCarrier ProteinsKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2TRIM24 protein, humanCRISPRa/dCas9LUSC treatment; NRF2PI3KαTRIM24

Identifiers

PMID40676628
PMCPMC12272974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.